S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains

Arcutis Biotherapeutics (ARQT) Earnings Date, Estimates & Call Transcripts

$10.25
+0.15 (+1.49%)
(As of 04/17/2024 ET)

Earnings Summary

Upcoming
Earnings Date
May. 14Estimated
Actual EPS
(Feb. 27)
-$0.72 Missed By -$0.08
Consensus EPS
(Feb. 27)
-$0.64
Skip Charts & View Estimated and Actual Earnings Data

ARQT Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

ARQT Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Arcutis Biotherapeutics Analyst EPS Estimates

Current Year EPS Consensus Estimate:($2.49) EPS
Next Year EPS Consensus Estimate: ($1.77) EPS

ARQT Earnings Date and Information

Arcutis Biotherapeutics last issued its earnings data on February 27th, 2024. The reported ($0.72) earnings per share for the quarter, missing the consensus estimate of ($0.64) by $0.08. The firm earned $13.53 million during the quarter, compared to analysts' expectations of $11.78 million. Arcutis Biotherapeutics has generated ($3.92) earnings per share over the last year (($3.92) diluted earnings per share). Earnings for Arcutis Biotherapeutics are expected to grow in the coming year, from ($2.49) to ($1.77) per share. Arcutis Biotherapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, May 14th, 2024 based off prior year's report dates.

Arcutis Biotherapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
5/14/2024
Estimated)
------- 
2/27/2024Q4 2023($0.64)($0.72)($0.08)($0.72)$11.78 million$13.53 million      
11/3/2023Q3 2023($0.90)($0.73)+$0.17($0.73)$9.54 million$38.11 million
8/8/2023Q2 2023($1.22)($1.16)+$0.06($1.16)$4.87 million$5.19 million
5/9/2023Q1 2023($1.30)($1.31)($0.01)($1.31)$3.50 million$2.78 million
2/28/2023Q4 2022($1.37)($1.18)+$0.19($1.18)$2.84 million$2.96 million
11/8/2022Q3 2022($1.54)($1.89)($0.35)($1.89)$1.01 million$0.73 million
8/4/2022Q2 2022($1.38)($1.31)+$0.07($1.31)--
5/5/2022Q1 2022($1.42)($1.27)+$0.15($1.27)--
2/22/2022Q4 2021($1.41)($1.42)($0.01)($1.42)--
11/4/2021Q3 2021($1.15)($1.14)+$0.01($1.14)--
8/5/2021Q2 2021($0.94)($0.84)+$0.10($0.84)--
5/3/2021Q1 2021($0.96)($0.76)+$0.20($0.76)--

Arcutis Biotherapeutics Earnings - Frequently Asked Questions

When is Arcutis Biotherapeutics's earnings date?

Arcutis Biotherapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, May 14th, 2024 based off last year's report dates. Learn more on ARQT's earnings history.

Did Arcutis Biotherapeutics beat their earnings estimates last quarter?

In the previous quarter, Arcutis Biotherapeutics (NASDAQ:ARQT) missed the analysts' consensus estimate of ($0.64) by $0.08 with a reported earnings per share (EPS) of ($0.72). Learn more on analysts' earnings estimate vs. ARQT's actual earnings.

How can I listen to Arcutis Biotherapeutics's earnings conference call?

The conference call for Arcutis Biotherapeutics's latest earnings report can be listened to online. Listen to Conference Call

How can I read Arcutis Biotherapeutics's conference call transcript?

The conference call transcript for Arcutis Biotherapeutics's latest earnings report can be read online. Read Transcript

How can I view Arcutis Biotherapeutics's earnings report?

Arcutis Biotherapeutics's earnings report can be found in their filing with the SEC. View SEC filing

How much revenue does Arcutis Biotherapeutics generate each year?

Arcutis Biotherapeutics (NASDAQ:ARQT) has a recorded annual revenue of $59.61 million.

How much profit does Arcutis Biotherapeutics generate each year?

Arcutis Biotherapeutics (NASDAQ:ARQT) has a recorded net income of -$262.14 million. ARQT has generated -$3.92 earnings per share over the last four quarters.

What is Arcutis Biotherapeutics's EPS forecast for next year?

Arcutis Biotherapeutics's earnings are expected to grow from ($2.49) per share to ($1.77) per share in the next year.


More Earnings Resources from MarketBeat

This page (NASDAQ:ARQT) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners